- Home
- NIXX vs CVKD Comparison
NIXX vs CVKD Comparison
Compare NIXX & CVKD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NIXX
- CVKD
- Stock Information
- Founded
- NIXX 2010
- CVKD 2022
- Country
- NIXX United States
- CVKD United States
- Employees
- NIXX N/A
- CVKD N/A
- Industry
- NIXX
- CVKD Medicinal Chemicals and Botanical Products
- Sector
- NIXX
- CVKD Health Care
- Exchange
- NIXX NYSE
- CVKD Nasdaq
- Market Cap
- NIXX 30.1M
- CVKD 33.7M
- IPO Year
- NIXX N/A
- CVKD 2023
- Fundamental
- Price
- NIXX $2.31
- CVKD $15.10
- Analyst Decision
- NIXX
- CVKD Strong Buy
- Analyst Count
- NIXX 0
- CVKD 1
- Target Price
- NIXX N/A
- CVKD $32.00
- AVG Volume (30 Days)
- NIXX 219.6K
- CVKD 23.6K
- Earning Date
- NIXX 05-20-2025
- CVKD 05-08-2025
- Dividend Yield
- NIXX N/A
- CVKD N/A
- EPS Growth
- NIXX N/A
- CVKD N/A
- EPS
- NIXX N/A
- CVKD N/A
- Revenue
- NIXX $1,786,387.00
- CVKD N/A
- Revenue This Year
- NIXX N/A
- CVKD N/A
- Revenue Next Year
- NIXX N/A
- CVKD N/A
- P/E Ratio
- NIXX N/A
- CVKD N/A
- Revenue Growth
- NIXX 54.16
- CVKD N/A
- 52 Week Low
- NIXX $1.35
- CVKD $5.70
- 52 Week High
- NIXX $8.50
- CVKD $22.90
- Technical
- Relative Strength Index (RSI)
- NIXX N/A
- CVKD 50.87
- Support Level
- NIXX N/A
- CVKD $13.00
- Resistance Level
- NIXX N/A
- CVKD $15.87
- Average True Range (ATR)
- NIXX 0.00
- CVKD 0.87
- MACD
- NIXX 0.00
- CVKD 0.13
- Stochastic Oscillator
- NIXX 0.00
- CVKD 72.41
About NIXX NIXXY INC
Nixxy Inc is a hiring platform for the network of recruiters. It empowers businesses to recruit specialized talent faster with virtual teams of recruiters and AI job-matching technology.Recently, the Company acquired the license from GoLogiq, Inc. (GoLogiq), to operate its fintech technology (the GOLQ Technology) and sell products derived thereof, including its Createapp, Paylogiq, Gologiq, and Radix AI technology and products.. Its Recruiters On Demand provides businesses of all sizes access to virtual recruiters specialized by vertical industries to source, engage, and hire talent on an as-needed basis.
About CVKD Cadrenal Therapeutics Inc.
Cadrenal Therapeutics Inc is developing tecarfarin, its drug candidate, for unmet needs in anticoagulation therapy. Tecarfarin is a late-stage novel oral and reversible anticoagulant (blood thinner) designed to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation.